Lactobacillus johnsonii La1 NCC533 (CNCM 1-1225) AND IMMUNE DISORDERS

FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates for composition for treatment or prevention of disorders, associated with reduced level of defensins. Composition contains from 0.005 to 1000 mg of Lactobacillus johnsonii Lal (NCC533, No CNCM 1-1225) per a daily dose, with at least 90% of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	NJUTTEN, SOFI, PRIU, GJUNOLE, GARSIA-RODENAS, KLARA, JULITA, MONIK, MERSEN'E, ANNIK, PTI, VALERI
Format:	Patent
Sprache:	eng ; rus
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FOODS OR FOODSTUFFS FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT THEIR TREATMENT, NOT COVERED BY OTHER CLASSES VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates for composition for treatment or prevention of disorders, associated with reduced level of defensins. Composition contains from 0.005 to 1000 mg of Lactobacillus johnsonii Lal (NCC533, No CNCM 1-1225) per a daily dose, with at least 90% of L. johnsonii Lal (NCC533, No CNCM 1-1225) being transferred into state in which they become non-replicating at temperature110-140°C for 5-30 s.EFFECT: invention provides enhancement of expression of defensin hBD1 mRNA.5 cl, 2 dwg Изобретение относится к композиции для лечения или предотвращения нарушений, связанных с пониженным уровнем дефензинов. Композиция содержит от 0,005 до 1000 мг Lactobacillus johnsonii Lal (NCC533, № CNCM 1-1225) на ежедневную дозу. Причем при температуре 110-140С в течение 5-30 с по меньшей мере 90% L. johnsonii Lal (NCC533, № CNCM 1-1225) переведены в состояние, при котором они становятся нереплицирующимися. Изобретение обеспечивает усиление экспрессии мРНК дефензина hBD1. 4 з.п. ф-лы, 2 ил.